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1 INTRODUCTION 
 
1.1 OBESITY 
1.1.1 PREFACE 
Chronic-degenerative diseases are nowadays in Italy the leading cause 
of death and requests for health care. Many of them, as indicated by the 
World Health Organization (WHO), are attributable to behaviors and 
lifestyles that are established from an early age, including improper 
eating habits, lack of physical activity and excess weight gain.  
Despite the degree of malnutrition on the planet, obesity is a major 
public health problem in the world. Indeed, we are facing a global 
epidemic that is spreading in many countries and it can cause, in the 
absence of an immediate intervention, serious health problems in the 
coming years.  
Obesity is a condition characterized by an excessive accumulation of 
body fat, usually due to poor diets and a sedentary lifestyle, even if the 
etiology of obesity reflects a complex interaction between genetic, 
metabolic, environmental, cultural, socioeconomic, and behavioral 
factors.  
 
1.1.2 DIAGNOSIS 
Fat mass evaluation 
An ideal measure of the visceral fat should be accurate, precise, easy, 
acceptable and well documented. Body fat expressed as percentage of 
total body weight is difficult to measure in the everyday practical clinic, 
and shows important variations in correlation to age and sex. The goal is 
to find a well-documented methodic with sharp cut-offs in order to 
correlate different populations. The most common used methods in the 
clinic practical are Body Mass Index (BMI) and waist circumference 
(WC): they are not direct measures of adiposity, but they have a strong 
correlation with other specific measures of body fat mass and are 
predictors of metabolic risk. 
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Among them, the Body Mass Index is currently the most used; it is 
calculated by dividing the subject's mass by the square of his or her 
height (kg/m2); the interpretation of the BMI suggested by WHO in 1997 
is listed in table below. 
 
BMI Classification 
< 18.5 underweight 
18.5–24.9 normal weight 
25.0–29.9 overweight 
30.0–34.9 class I obesity 
35.0–39.9 class II obesity 
≥ 40.0 class III obesity  
 
In contrast to what happens to the adult BMI values in childhood are 
constantly changing depending on gender and age. BMI in children is 
calculated the same way as adults, but compared to typical values for 
other children of the same age (Cole BMI charts, Cole et Al., 2000): 
according to the American Academy of Pediatrics, people under 5th 
percentile for BMI are considered to be underweight, people between 
85th and 95th percentile are considered to be overweight, while children 
over 95th percentile are considered to be obese. 
Waist circumference estimates visceral adipose tissue and correlates 
with the risk of metabolic disease even in children. Today the most 
widely used index is the waist to height ratio (high values > 0,5), more 
immediate and simple compared to the value of percentile or z-score of 
waist circumference. 
Anamnestic evaluation 
Each patient must be subject to a thorough medical history for a correct 
diagnosis. The family history detects weight and height of parents and 
brothers: the presence of obesity in a first-degree relative is one of the 
most important risk factors for the onset of obesity in children and 
increases the risk of persistence of obesity with the growth. The 
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presence of diseases and cardiovascular risk factors in first-degree 
relatives should be investigated, as well as the presence of diabetes 
mellitus, endocrine disorders or eating disorders.  
The personal history detects problems related to pregnancy (including 
mother’s weight gain during pregnancy), birth weight (very high or 
very low weight at birth are risk factors for the maintenance of excess 
weight in later years), the trend of height and weight growth and 
psychomotor development (its delay may reflect the presence of 
syndromic obesity), an early adiposity rebound, any regular use of 
medications and breathing or sleep-related problems. 
The behavioral history detects the mode of feeding (breastfeeding or 
bottle feeding) and the weaning period (as noted, precocious weaning, 
hyperalimentation and excess of protein intake lead to the development 
of obesity), a qualitative and quantitative assessment of the risk 
behaviors of the child and the family, including information regarding 
nutrition, physical activity and sedentary lifestyle. 
 
Clinical evaluation 
The physical examination should be carefully conducted: it must 
therefore investigate weight, height, BMI and waist circumference, 
skinfold thickness and height percentile of the annual rate of growth (for 
evidence of short stature or stunting, generally not compatible with a 
diagnosis of essential obesity), arterial blood pressure, appearance of 
genital and pubertal stage, the presence of dysmorphic features or 
abnormal psychomotor development and any other clinical features 
such as the presence of acanthosis nigricans, striae rubrae, 
hypertrichosis (which are correlated with endocrine etiology). 
 
Instrumental and laboratory evaluation 
The American Heart Association and the American Academy of 
Pediatrics recommend an assessment of blood parameters in overweight 
and obese child after two years of life. These investigations include the 
assessment of first level like glycemic profile, lipid profile, liver profile; 
among investigations of second level, assessment of insulin resistance 
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and liver ultrasound are recommended. In case of detection of fasting 
hyperglycemia, glycosylated hemoglobin and oral glucose tolerance test 
(OGTT) are recommended. If there are any signs or symptoms 
correlated to secondary obesity, complications related to the disease in 
question will be investigated 
 
1.1.3 DIFFERENTIAL DIAGNOSIS 
As mentioned before, it is always easier to find excess weight in young 
children. It’s 'well known that most of the times we are faced with a case 
of essential obesity (about 95% of cases); however, the early onset of 
obesity in children may be due to a secondary form, underlying causes 
that have to be carefully investigated and excluded. 
 
Endocrine obesity 
Endocrine dysfunctions that play a pathogenic role in obesity of early 
onset are rare (less than 1% of all obesity), but they must be recognized 
early in life in order to allow an adequate and timely treatment. In these 
cases, the excess weight is generally linked to signs and symptoms that 
may alert clinicians to the correct diagnosis. 
The clinical or subclinical hypothyroidism is relatively common in the 
first months or years of life. In cases of clinical hypothyroidism, it can 
easily show symptoms related to the disease (such as dry skin, 
constipation, somnolence, apathy, hyporeactivity...); the dosage of 
thyroid hormones is easily able to confirm the diagnosis. 
The hyperadrenocorticism, either by adrenal and hypothalamic-
pituitary origin (Cushing's syndrome and disease), is very rare in the 
early stages of life; Cushing's syndrome is most often iatrogenic, due to 
abuse of preparations of steroids. This disease should always be 
suspected in the presence of a low stature with growth retardation of 
bone age, tendency to accumulate fat in the trunk and abdomen, the 
presence of striae rubrae in the abdominal region, hips, thighs and 
mammary region and blood pressure higher than normal. Basal adrenal 
function tests and high urinary free cortisol help to direct a possible 
adrenal dysfunction. 
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The presence of early onset obesity in the first years of life can also be 
the first sign of an organic disease of the hypothalamic-pituitary region 
(craniopharyngioma and pituitary adenoma), when the excess weight 
has risen rapidly and is associated with sudden slowdown in growth 
velocity or signs of intracranial hypertension. In these cases, an imaging 
examination such as MRI is able to confirm or rule out the suspected 
diagnosis. 
Among the more rare forms of obesity etiology endocrine, we recall the 
presence of pseuohypoparathyroidism, GH deficiency and 
nesidioblastosis. 
 
Genetic obesity 
The presence of obesity in a child associated with other features such as 
mental retardation, short stature, cryptorchidism or hypogonadism, 
dysmorphic features and other changes, can lead to think of a form of 
obesity on a genetic basis, which must be supported by specific 
investigations in the diagnosis. 
Prader-Willi syndrome is the most frequent of these conditions (with a 
prevalence of 1:20000) and is due to an alteration of chromosome 15 of 
paternal origin. In the first months of life the diagnostic suspicion is 
supported by reduced fetal movements, neonatal hypotonia, lethargy, 
weak cry, difficulty in feeding and psychomotor retardation; the 
suspected diagnosis must be confirmed with the methylation test. In 
these patients obesity is evident after 2-3 years of age and is 
accompanied by hyperphagia, mild to medium mental retardation, 
hypogonadism. 
Another form of rare genetic disease related to obesity is the Bardet-
Biedl syndrome (prevalence 1:100,000), with an autosomal recessive 
transmission, which is characterized by excess weight associated with 
visual disturbances (very frequently retinitis pigmentosa), or alterations 
of color vision, often in the presence of polydactyly. Other forms of 
syndromic obesity include Cohen Syndrome and Syndrome Alstrom. 
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1.1.4 EPIDEMIOLOGY 
Worldwide there are over 155 million overweight or obese children, and 
the prevalence of obesity has remarkably increased over the past two 
decades. The number of overweight children in EU countries is expected 
to rise by 1.3 million per year, with more than 300,000 children 
becoming obese each year without urgent action to counteract the trend 
(Toselli et Al, 2012). In Italy, in 2005 on a sample of 60 000 families, 34% 
of adults was overweight and 10% obese, showing an increase of 9% 
compared to the values obtained in 2000; as regards children, in a 
research conducted in 2008-2009, 23,2% were considered overweight 
and 12% were obese, with great differences among southern regions if 
compared with northern regions (Spinelli et Al., 2012).   
 
This trend leads to serious consequences on the health status of the 
population, with a progressive increase in patients with diabetes, 
cardiovascular disease and cancer because obesity and overweight are 
one of the main risk factors for other chronic diseases including type 2 
diabetes through the promotion of insulin resistance, cardiovascular 
diseases, hypertension and stroke and certain forms of cancer (Agostoni 
et Al, 2011). Consequently it will bring serious consequences on the 
Overweight Obese 
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financial statements of the States, affecting economic and social 
development both for the rising costs of health care (with more than 6% 
of the costs in each European country), and reducing productivity in 
work and income. It has been estimated that in 2030, the health costs 
associated with obesity-related diseases will rise of 48-66 billion of 
dollars only in the United States. An early identification of subjects at 
risk could can prevent the development of those pathologies, ensuring 
better quality of life. The problems related to overweight and obesity 
must be addressed according to a cross-sectional approach, paying 
attention not only to the aspects specifically linked to health, but also 
environmental, social and economic determinants. The prevention 
strategy should start from an early age, because early adiposity 
accumulation (in the first 5 years of life) is one of the individual risk 
factors for the development of obesity. 
 
1.1.5 COMPLICATIONS 
It’s well known that in the adult subjects obesity predisposes to chronic 
diseases and complications that can lead to increased mortality 
compared with age-matched normal weight subjects. However, in the 
child we cannot speak of a real risk of mortality, but given the high 
persistence of pediatric obesity in adulthood, it is fair to assume that the 
changes have arisen in the early ages of life are correlated with 
morbidity in the long term. In Western countries, the adult mortality is 
mainly due to cardiovascular diseases: the main risk factors are high 
blood pressure, atherosclerosis, dyslipidemia, and diabetes mellitus. All 
this metabolic abnormalities are commonly associated with obesity and 
are known to regress with weight loss. The obese child after a few years 
presents some metabolic abnormalities: first of all are insulin resistance, 
impaired glucose tolerance and type 2 diabetes. 
Insulin resistance is a condition characterized by the inability of insulin 
to adequately stimulate the entrance of glucose into the cells; the result 
is a decreased utilization of glucose that accumulates in the circulation 
and further stimulates the secretion of insulin. In a first phase, 
hyperinsulinemia favors the cellular uptake of glucose, which is still 
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able to maintain normal blood glucose values. Subsequently, blood 
glucose levels become progressively more pronounced with further 
increase in insulin secretion: in this phase appears glucose intolerance. 
Finally, the appearance of high postprandial blood glucose values, 
which do not result in an adequate pancreatic response, leads to the 
onset of diabetes mellitus type 2; the lower peripheral glucose 
utilization also results in a down regulation of insulin receptors and a 
lower use of liver glycogen. 
The metabolic syndrome is a clinical situation frequently encountered in 
obese adults, characterized by the presence of insulin resistance, glucose 
intolerance, dyslipidemia and hypertension. This condition is associated 
with morbidity and mortality from cerebral vascular diseases, cardiac 
and peripheral devices. The child suffering from obesity can also 
develop metabolic syndrome, although the young subject shows less 
clear features. 
With regard to dyslipidemia, obese subject presents circulating levels of 
free fatty acids higher than in normal-weight person, due to the inability 
of insulin to inhibit their release into the circulation. High blood 
pressure is not common in obese child, although his pressure values are 
significantly higher than in normal-weight person; on the other hand,  
insulin resistance and hypertension are strictly associated in adults. 
The circadian rhythm of cortisol is normally preserved, but elevated 
levels of excretion of metabolites of cortisol and corticosterone can be 
documented, resulting in increased secretion of ACTH and increased 
production of adrenal androgens, that can lead to early adrenarche in 
these children. The child with essential obesity usually does not present 
growth failure: during the prepubertal period they are often taller than 
their peers. The adrenarche is usually anticipated, but sexual 
development is normal. In the female instead menarche is often 
anticipated, often followed by changes in the menstrual cycle such as 
secondary amenorrhea and dysmenorrhea. Relatively common is 
polycystic ovary syndrome, characterized by the presence of numerous 
ovarian cysts with a diameter greater than 4 cm or oligomenorrhea 
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associated with dysmenorrhea, signs of hyperandrogenism and 
hyperinsulinemia. 
In children with important obesity drowsiness, hypercapnia, hypoxia 
and congestive heart failure secondary to pulmonary hypertension are 
described. The limitations resulting from the decrease in lung 
compliance commonly lead to easy fatigability and dyspnea during the 
practice exercise. 
Other long term complications strongly linked to obesity are known to 
be musculoskeletal diseases such as arthrosis and chronical orthopedic 
problems, nefrosic syndrome and oncological diseases.  
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1.2 METABOLIC SYNDROME 
 
Metabolic syndrome is defined as a cluster of risk factors for 
cardiovascular disease and type-2 diabetes mellitus occurring in the 
same individual; it includes elevated blood pressure, atherogenic 
dyslipidemia (raised triglycerides and lowered HDL-cholesterol), raised 
fasting glucose  and abdominal obesity (Pacifico et Al., 2013). The 
syndrome is associated with a two-fold increase for the risk of 
cardiovascular diseases and a five-fold increase for the risk of type-2 
diabetes mellitus. Therefore, it is alarming to see that the prevalence of 
metabolic syndrome is reaching epidemic proportions worldwide. 
Moreover, MS typically regarded as a middle to late adulthood disorder, 
is now emerging in adolescence with close to 10% of all 12-19 years old 
being affected. There is no universally accepted definition of MS in 
children and adolescents (Zimmet et Al., 2007; Goodman et Al., 2007). 
The International Diabetes Federation and American Heart Association 
have both recently proposed a revised definition of MS in children and 
adolescents (see table below). In both guidelines, waist circumference 
was assessed by percentiles, and the cut-offs for metabolic and blood 
pressure variables were defined only for children above 10 years of age. 
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The dyslipidemia associated with metabolic syndrome consists of both 
high triglycerides and low high-density lipoprotein cholesterol (HDL) 
levels, the so called atherogenic dyslipidemia (Bacha F et Al., 2003). 
Obesity and insulin resistance are thought to promote atherogenic 
dyslipidemia by enhancing the hepatic synthesis of the triglyceride-rich 
very low-density lipoproteins (VLDL). In addition, the activity of 
lipoprotein lipase e the enzyme that catabolizes VLDL and generates 
HDL particles is impaired in the insulin resistant state, further 
contributing to raise triglycerides and lower HDL levels (Steinberger J et 
Al., 2009). 
The primary treatment for the dyslipidemia associated with metabolic 
syndrome is behavioral: weight management and exercise. This 
approach is strongly supported by evidence indicating that obesity 
during childhood is related to unfavorable changes in plasma 
triglycerides and HDL, and that fitness may enhance clearance rate of 
plasma triglycerides and production of HDL particles. 
Glucose abnormalities, defined as impaired fasting glucose or impaired 
glucose tolerance, represent, by definition, a major component of 
metabolic syndrome. As with adults, they are strongly related with 
obesity and insulin resistance in children. Lifestyle modifications 
including dietary changes and improvements in physical activity are the 
mainstay of treatment of glucose abnormalities in children with 
metabolic syndrome. Whole-grain intake has been associated with 
greater insulin sensitivity and lower BMI in adolescents. Fiber in 
particular attenuates postprandial glycemic excursions and has 
beneficial effects on insulin sensitivity, adiposity, and pancreatic 
function. Children should be encouraged to add at least five fruits and 
vegetables per day, and minimize or eliminate sweetened beverages. 
Most importantly, high-fat and high-calorie food items should also be 
minimized. Physical activity is considered a cornerstone in the 
prevention of diabetes mellitus type 2 by improving insulin sensitivity 
and through direct effects on glucose uptake in the skeletal muscle. 
Recent studies in adolescents have shown that physical activity is 
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positively associated with improved glucose metabolism and resting 
energy expenditure and negatively associated with IR-dependent 
metabolic parameters (Sinha et Al., 2002).  
The prevalence of hypertension among obese children is estimated to be 
as high as 11% (Sorof et Al., 2004). Diastolic blood pressure has been 
shown to be a function of increasing abdominal circumference. A 
successful treatment of hypertension in children and adolescents with 
metabolic syndrome requires a multifaceted approach, beginning with 
non-pharmacological measures, including weight loss, exercise, and 
dietary modifications: Studies in obese adolescents have demonstrated 
that moderate weight loss decreases blood pressure, either systolic and 
diastolic (Reinehr T, Andler W, 2004). Pharmacologic management is 
reserved to pediatric patients who do not respond to a lifestyle 
modification. 
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1.2 VISCERAL FAT 
 
Epidemiologic evidence supports the theory that the relation between 
obesity and disease risk begins early in life. For example, in young 
adults who died in accidents, fatty streaks in the coronary arteries and 
aorta that were found at autopsy were associated with blood lipid 
profile, blood pressure, and obesity status obtained at one or more 
points antemortem (Tracy et Al., 1995). Additional longitudinal data 
indicate that the occurrence of overweight, hypertension, and 
dyslipidemia in young adults (aged 19–32 y) was associated with these 
same risk factors in childhood (Pinhal-Hamiel O et Al., 1996). The 
evidence indicates that obesity-related disease can begin in childhood 
and that risk factors for disease track, or remain at a similar level, with 
advancing age, growth, and development. The relation between obesity 
and disease was noted as early as 100–200 BC by Samhita and 
Ayurveda, who observed the relation between glycosuria, obesity, and 
lifestyle. In 1717, Morgagni noted the android fat pattern in the corpse of 
a woman and in 1947, Vague described the metabolic risk of android 
obesity as compared with the protective nature of gynoid obesity 
(Vague et Al., 1988). 
Adipose tissue stores are heterogeneous with respect to metabolic 
activity and relation to disease risk. Deeper analysis have shown that, 
not only the total, but the distribution of excessive adipose tissue seems 
to determine the development of these comorbidities and, therefore, 
abdominal obesity is pointed out as more harmful to human health than 
subcutaneous adipose tissue. The specific fat deposit most related to 
negative health effects is visceral fat (VF), also referred to as intra-
abdominal adipose tissue mass IAAT). Visceral fat is metabolically 
unique when compared with subcutaneous adipose tissue. The 
increased sensitivity to lipolytic stimuli like norepinephrine and its 
proximity to the hepatic portal vasculature are hypothesized to be 
responsible for the positive association between visceral fat, 
dyslipidemia, hyperinsulinemia, and glucose intolerance. By 
contributing free fatty acids to the liver, visceral fat leads to increased 
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circulating triglycerides (TG), decreased high density lipoprotein, 
increased hepatic glucose production, and decreased hepatic insulin 
extraction, hence predisposition to metabolic syndrome. Thus 
reductions in waist circumference, in addition to overall obesity, should 
be a target for intervention to reverse obesity-related health risks in 
general population. Essentially, all successful programs include 
interventions to reduce calorie intake and increase physical activity. 
Dietary modification should be age-specific, providing appropriate 
optimum nutrient intake for the maintenance of healthy linear growth 
and normal development. Recommendations include a moderately 
reduced calorie intake while maintaining a well-balanced diet. The 
increase of physical activity must be also considered as part of the 
treatment, based on the mounting evidence in adults which 
demonstrates the benefits of regular physical activity on abdominal 
obesity. However, the role of regular physical activity alone (e.g., 
without calorie restriction) on abdominal obesity, and in particular 
visceral fat, is largely unclear in youth. There is some evidence to 
suggest that engaging in higher-intensity physical activity is associated 
with a lower waist circumference and less visceral fat. Randomized 
controlled studies have also shown that aerobic exercise is protective 
against age-related increases in visceral adiposity in growing children 
and adolescents. However, evidence regarding the effect of resistance 
training alone as a strategy for the treatment of abdominal obesity is 
lacking and warrants further investigation. 
The commonly used imaging modalities to measure visceral fat are 
ultrasonography (US), computerized tomography (CT) and Magnetic 
Resonance Imaging (MRI). With these approaches, adipose tissue is 
measured in terms of cross-sectional area (cm2) or volume (cm2). Because 
these techniques are expensive and CT involves radiation  exposure, 
intra abdominal adipose tissue is often measured in a single, cross-
sectional slice at an anatomic landmark, usually the level of the 
umbilicus or the L3–L4 disk space. The major advantages of these 
imaging techniques are the high resolution of the images and the 
capability to identify small deposits of visceral fat. In addition, 
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subcutaneous abdominal adipose tissue (SAAT) is also accurately 
quantified at the same time. Indirect measures of intra abdominal 
adipose tissue also include dual energy X-ray absorptiometry (DXA) to 
measure fat mass in the trunk region and anthropometric measures 
(circumferences and skinfold thicknesses). Generally speaking 
computed tomography is considered as the gold standard for visceral 
fat measurement, but because of the radiation problem and economic 
reasons, ultrasonography is often preferred for visceral fat estimation in 
children. In adults the waist-to-hip ratio and waist circumference are 
often used as markers of visceral fat, even if WC reflects not only the 
quantity of fat but also the quantity of lean body mass (muscles, bones 
and internal organs) and cannot distinguish between subcutaneous and 
visceral fat. As such, waist circumference may misclassify visceral 
obesity: there are individuals who have a normal WC but an excessive 
amount of VF and high risk for metabolic syndrome, and individuals 
who have a large WC but a normal amount of intra abdominal visceral 
fat and low risk for metabolic syndrome. However, in children and 
adolescents the correlation between these markers and visceral fat as 
measured by imaging techniques is not strong. A close relationship 
between high morbidity and intraabdominal (visceral) fat obesity, rather 
than extra-abdominal (subcutaneous) fat obesity, has been observed in 
adults in several studies. Although body fat patterning has been related 
to adverse health outcomes in adults, its importance in children and 
adolescents is less certain. If visceral fat accumulation rather than 
general fat accumulation is a more direct predictor of human 
cardiovascular disease in adulthood, then an early measure of this fat 
deposit may be useful in identifying an individual at increased risk. 
Some studies suggest that IAAT in children increases in proportion to 
overall fatness as measured in adults, whereas other studies showed 
that obese children tend to accumulate subcutaneous fat and not IAAT. 
The influence of dietary factors on visceral fat accumulation has not 
been extensively studied in children. Physical activity indeed is an 
important determinant of intra abdominal adipose tissue.  
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Growth during childhood is known to be a time of rapid change in body 
composition; however, there have been few longitudinal studies that 
examined changes in specific fat compartments during the growth 
process. The study of change of various compartments of fat is 
important because it helps to elucidate the dynamics of growth in 
children and how changes in body composition may be related to health 
outcomes. This is especially important for the growth of visceral fat, 
which may contribute to metabolic disease risk. In children, visceral fat 
has been shown to be positively related to a wide range of health 
indicators, including total cholesterol, low-density lipoprotein 
cholesterol, triacylglycerol, insulin areas after an oral glucose test, basal 
insulin secretion, and stimulated insulin secretion; In addition, visceral 
fat seems to have a negative relationship with insulin sensitivity and 
high-density lipoprotein cholesterol. Although some associations 
between different adipose tissues and risk factors have been identified, 
how visceral fat or subcutaneous abdominal fat is acquired in children 
and the mechanisms through which visceral fat or subcutaneous 
abdominal fat affect disease risks are still unclear: there have been few 
previous reports from longitudinal studies that examined the growth 
trajectory of visceral fat or subcutaneous abdominal fat in children.  
With the use of imaging techniques for direct measurement of intra 
abdominal adipose tissue, several Authors (Kissebah et Al., 1982; 
Després et Al., 1984; Björntorp, 1992; Vague et Al., 1988) reported in the 
1980s and early 1990s that excess visceral fat explains the relation 
between obesity and metabolic complications in adults, but first studies 
conducted in children start to be published in nineties: the first study 
that has investigated the distribution of body fat in subjects in childhood 
is from de Ridder et Al in 1992., in which the Authors postulated waist 
circumference to be a good good measure for the related amounts of fat 
in pubertal girls. Differences in body fat accumulation have been noted 
with boys having more visceral abdominal tissues during evolutive age 
than girsl (Kotani et Al., 1994, Goran et Al., 1995). Goran concluded his 
study supporting that individual trunk skinfold measurements and the 
trunk/extremity skinfold ratio provide a better indication of IAAT 
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compared to the waist/hip ratio, even if the relationship between intra-
abdominal adipose tissue and anthropometry in children is complex. 
First study to investigate the relationship between viscerl fat 
accumulation in evolutive age and metabolic derangements has been 
published in 1995 (Caprio S et Al., 1995), where the Authors noted that 
in obese girls, visceral fat, but neither waist-to-hip circumference ratio 
nor subcutaneous fat, was highly correlated with basal insulin secretion, 
stimulated insulin secretion, and insulin resistance. On the other hand, 
Iwata in his study concluded that visceral fat obesity is a rare status and 
has no close relationship to coronary risk factors in childhood (Iwata F 
et Al., 1995), while Ellis in 1997 published a paper in which underlinewd 
the role of VAT as a potential early marker for cardiovascular diseases 
(Ellis KJ, 1997). In the following years publication about visceral fat in 
children and its relationship with other anthropometric measurements 
and metabolic derangements have been published, but still there’s not 
univocal consent about it. 
Nutritional status in children can be evaluated by means of simple 
anthropometric assessment methods. Body Mass Index, an index of 
excess weight relative to height, has a moderately high sensitivity for 
the general identification of the obese child, but a weak correlation with 
total body fat due to considerable changes in fat mass that occur during 
childhood. Other simple body composition assessment methods are 
needed to investigate the metabolic risk for young patients. 
 
19 
 
2 AIMS OF THE STUDY 
 
In this study we wanted to see the correlation between anthropometric 
measures and visceral fat assessed by ultrasonography in a large 
population of children; furthermore we wanted to see the clinical 
correlation of visceral fat accumulation in childhood obesity with 
respect to the development of metabolic derangements, compared to 
body mass index and waist circumference. At last, we wanted to 
investigate the effects of visceral fat accumulation in developmental age; 
in particular we supposed that, like in adults, the increment of 
abdominal visceral fat, measured by ultrasonography, is associated with 
a worsened metabolic profile and with the increment of metabolic 
syndrome risk. 
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3 RESULT AND DISCUSSION 
 
3.1 MATHERIALS AND METHODS 
 
This study was undertaken in The International Center for the 
Assessment of Nutritional Status (ICANS) of Milan, Italy.  
We considered a sample of 83 patients who spontaneously referred to 
ICANS for valuation of nutritional status and dietary treatment in case 
of overweight, obesity or nutritional counseling divided in 58 females 
and 28 males, with age range 11-17 and mean age of 14,6 years. None of 
them was affected by acute or chronic disease; those with overweight 
syndromes, overweight secondary to underlying disorders, those with 
eating disorders (either over or underweight) and those on longterm 
drugs were excluded from the study. The history was obtained from the 
parents/guardian and physical examination was performed as per the 
protocol. 
All the patients were subject to anthropometric measurements of 
weight, height and BMI. Body weight and body height were measured 
to the nearest 0,1 Kg and 0,5 cm respectively; they were measured while 
the subjects were fasting and wearing light clothes without shoes. 
Weight was assessed with a balance-beam scale and height with a 
stadiometer; for the statistical analysis we calculated z-score for both 
weight and height.  
Body Mass Index was calculated as weight (kilogram) divided by square 
of height (meter), and then for every patient z-BMI was calculated. The 
degree of over nutrition was quantified using reference chart (Cole et al) 
on BMI for male/and female children of age 2–18 years.  
Waist circumference was also considered for everyone: it was measured 
to the nearest 0,1 cm with a non-elastic tape while the participant was 
standing at the end of normal expiration and at the midpoint between 
the last rib and the crest of the ilium in a horizontal plane. Waist 
circumference has been quantified with reference charts for age and sex 
and z-waist circumference was calculated. Waist to height ratio was 
calculated for every patient. 
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Skin folds (biceps, triceps, subscapular and suprailiac) were measured 
in every child in triplicate, as proposed by Lohman using a Holtain Ltd 
skinfold caliper. Systolic and diastolic blood pressure were measured 
three times while the subjects were seated, and the measurements were 
averaged for the analysis. 
For air-displacement plethysmography we used a BOD POD 
instrument (BOD POD ® Body Composition System, Life Measurement 
Instruments, Concord, CA, USA) to measure body volume and thoracic 
lung volume. The BOD POD software (version 1.69) calculated whole 
body density as body weight divided by body volume and fat mass 
percentage using Siri’s quation. 
Dual Energy X-ray Absorptiometry (DEXA) was performed using a 
Lunar DXP-IQ whole body absorptiometer (Lunar Corporation, 
Madison, WI, USA): patients laid down with arms and legs at their 
sides during the 15-min scan, with a radiation exposure < 7 µSv. 
Manufacturer’s software version 4,6b was used, and daily quality-
assurance tests were performed according to the manufacturer’s 
directions. 
Bioelectrical Inpedance Analysis (BIA) was measured using a 
tetrapolar, multifrequency BIA system (InBody 170, InBody Australia, 
Miami, Queensland, Australia) introducing an alternating current (20 
and 100 Khz) at the base of the toes and fingers. Patients were standing 
with upper and lower arms slightly abduced for positioning of the 
electrodes. Impedance index was calculated as BH2 divided by 
segmental impedance (m2/ohm).  
Ultrasound measurement was done on empty stomach in supine 
position and visceral fat was measured at the end of normal expiration 
with vertebral column positioned horizontal. The transducer was placed 
vertically and as lightly as possible to prevent compression of fat layers. 
Each measurement was performed 3 times and the average was 
considered for calculations. According to Armellini et al., we considered 
measurements of abdominal subcutaneous skin-hepatic thickness (pre-
hepatic AT), abdominal subcutaneous skin-muscle thickness (umbilical 
AT), intra-abdominal muscle-aorta thickness (Aortic AT).  
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Blood samples were collected in the morning after overnight fasting for 
all the subjects included in the study. Metabolic biomarkers included 
total cholesterol, high density lipoprotein cholesterol (HDL), low 
density lipoprotein cholesterol (LDL), triglycerides (TG), fasting blood 
glucose, insulin, renal function as creatinine and blood urea nitrate, 
hepatic function as glutamic pyruvic transaminase (GPT), glutamic 
oxaloacetic transaminase (GOT) and gamma glutamyl transpeptidase 
(GGT). GOT levels were considered to be normal until 35 IU/L, GPT 
level until 38 IU/L and GGT levels were considered to be normal until a 
value of 42 IU/L. Cardiometabolic risk factors were identified as follows: 
hyper-triglyceridemia was defined as fasting triglycerides ≥150 mg/dl; 
low HDL-cholesterol as fasting HDL <40 mg/dl; hyperglycemia as 
fasting glucose ≥100 mg/dl. Homeostasis model assessment of insulin 
resistance (HOMA-IR) was calculated for each patient using the formula 
fasting insulin (mIU/l) x fasting glucose (mg/dl)/405. Each patient was 
evaluated according to the criteria of the metabolic syndrome; metabolic 
syndrome was considered according to the International Diabetes 
Federation (IDF) criteria:  
- in children aged between 6 and 10 years, the metabolic syndrome is 
an entity that cannot be diagnosed, but the presence of a waist 
circumference higher than the 90th percentile and familiarity for 
metabolic syndrome, diabetes mellitus, or dyslipidemia are warning 
signs 
- in children aged between 10 and 15 years, metabolic syndrome is 
defined by the presence of a waist circumference greater than the 
90th percentile and the presence of at least two of the following 
signs: hypertriglyceridemia (≥150 mg/dl), hyperglycemia (≥100 
mg/dl), low HDL (<40 mg/dl) or high blood pressure (≥130 mmHg 
for the systolic and ≥85 mmHg for the diastolic) 
- in subjects over 15 years, the metabolic syndrome is considered in 
the presence of waist circumference greater than the 90th percentile 
associated with the presence of at least 2 of the following signs: 
triglyceridemia ≥150 mg/dl or pharmacological treatment for 
hypertriglyceridemia, fasting glycemia ≥100 mg/dl or diabetes 
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mellitus type 2, HDL <40 mg/dl for males and <50 mg/dl for females 
or pharmacological treatment for low HDL, blood pressure ≥130 
mmHg for the systolic and ≥85 mmHg for the diastolic or 
pharmacological treatment for arterial hypertension 
Statistical analysis was conducted using SPSS-20; correlation co-efficient 
and its significance were assessed between anthropometric 
measurements (z-height, z-weight, z-BMI, z-waist circumference and 
skin folds), visceral fat (prehepatic, umbilical) and blood values. Linear 
regression was used for those values which showed significant positive 
correlation. Logistic regression was used to estimate odds ratio between 
VAT and metabolic derangements. P value <0.05 was considered 
significant.  
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3.2 RESULTS 
 
The characteristics of our group of patients are presented in Table 1. The 
mean age of the sample was 14,6 years (range 11–17 years), the same for 
the two subgroups females and males (p 0,807). The mean BMI z-score 
was 1,38 (± 0,7) for the whole cohort, 1,70 (± 0,77) and 1,25 (± 0,63) for 
males and females, respectively (p 0,007). Prevalence of overweight and 
obesity (BMI z-score higher than 1,036 and 1,645, referred to 85° 
percentile and 95° percentile of Center for Disease Control BMI charts) 
was 32,5% and 38,5% for the total of the patients respectively; for what 
concerns males and females, we found 16% (4/25) of overweight and 
68% (17/25) of obese in the males, and 39,6% (23/58) and 25,8% (15/58) 
for the females, as reported in the table 3, resulting the prevalence of 
obesity to be significantly higher in our cohort in males than females (p 
< 0,05). 
In addition, the overall sample had a mean value of 26,7 ± 9,4 kg for 
total body fat measured with DEXA, 2,84 ± 1,13 cm for subcutaneous 
abdominal fat and 3,32 ± 1,35 cm for visceral fat measured with 
ultrasound. Student’s t tests revealed that boys had significantly higher 
visceral fat (4,18 ± 1,70 cm vs. 2,95 ± 0,96 cm; p ,< 0.05), including 
VAT/SAT ratio. After matching patients from the two genders in order 
to eliminate initial differences of z-BMI, the group of males still presents 
significantly higher mean VAT compared to females (4,18 cm vs, 3,30 cm 
respectively, p < 0,05). Total fat free mass and trunk fat/limbs fat ratio 
were also significantly higher in males than in females. No other 
significant differences were found between gender of patients. All 
results regarding anthropometric measurements by gender  are shown 
in table 1. 
In the table 2 we show the distribution of biochemical markers in our 
population of patients, divided for sex. Mean values of lipid profile, 
glycemia, insulin and hepatic function are under upper limits, but mean 
values of HOMA index are high for the general population and for both 
males and females group.  
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Statistically significant correlations between males and females are also 
shown in table 2. The two genders have similar total cholesterol and 
LDL profile, but differences are evident for all the other parameters. 
Males have lower mean HDL profile (50 mg/dL ± 12,4 vs. 61 mg/dL ± 
12,7) compared to females, and higher tryglicerides (105 mg/dL ± 143, 1 
vs. 63 mg/dL ± 29,1), fasting glucose (93 mg/dL ± 6,1 vs. 86 mg/dL ± 6,6), 
insulin (17 mIU/l ± 12,2 vs. 11 mIU/l ± 6,1), insulin resistance intended as 
higher HOMA index (4,16 ± 3,08 vs. 2,51 ± 1,42), GOT (23 IU/l ± 5,0 vs. 18 
IU/l ± 5,2), GPT (24 IU/l ± 8,8 vs. 16 IU/l ± 6,8) and γGT (21,4 IU/l ± 11,1 
vs. 12 IU/l ± 6,6). 
Table 3 presents the proportion of participants with each metabolic risk 
factor; in the last line we reported the prevalence of metabolic syndrome 
in our sample of patients and its distribution among females and males, 
considering which subject had more than two risk factors associated to 
high waist circumference, as defined by IDF criteria for metabolic 
syndrome in evolutive age. The prevalence of metabolic syndrome 
among the two genders is significantly different: 25% of  males (6/25) 
presented with the criteria for metabolic syndrome, while none of the 
females (0/58) could be included with the criteria of metabolic 
syndrome.   
Bivariate analysis (Table 4) indicated that our anthropometric  
measurements of abdominal fat (superficial abdominal tissue, visceral 
abdominal tissue, VAT/SAT, fat percentage, total fat and trunk/limbs 
fat) were directly significantly associated with the following 
anthropometric measurements: BMI z-score and waist circumference z-
score. In particular, in the linear regression model, VAT was 
significantly associated to all the other anthropometric measurements 
with a significant correlation, even if adjusted for age and sex and with 
physical activity level (table 5 to 7 and graphs 1 to 6). 
As regards metabolic derangements, visceral abdominal fat, 
subcutaneous abdominal fat and their ratio VAT/SAT were correlated to 
blood values in a linear regression model adjusted for BMI z-score. VAT 
demonstrated to be superior than SAT and VAT/SAT in dectecting 
blood abnormalities, as it had significant correlation with fasting 
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glycemia, insulin, HOMA index and γGT, while VAT/SAT ratio only 
with insulin and HOMA, and SAT with GOT. None of the other blood 
values were positively correlated with visceral fat measurements. All 
the results are showed in table 8. 
In order to see if visceral fat could be a major risk for metabolic 
derangements and for metabolic syndrome, we calculated odds ratio 
(OR) for VAT compared to MS and its criteria in evolutive age (high 
fasting glucose, low HDL cholesterol, high triglycerides and high 
arterial blood pressure) and other blood biomarkers such as liver 
enzymes. We didn’t see any significant statistical correlation, excepted 
for the relationship between visceral fat and γGT, which showed a 
positive significant correlation with an odds ratio of 11,3. We also 
wanted to test if other indirect fat measurements could be a risk factor 
for metabolic derangements, but waist circumference didn’t show any 
significant OR with the studied variables, while total fat measured with 
DEXA showed a significant correlation with γGT as well as found with 
VAT measured by ultrasonography. At last, we tried to calculate OR 
between VAT measure and the median of all blood biomarkers for our 
patients, in order to see if we could find an increased risk of higher 
blood values (but not considered pathological) for lipid status, liver 
enzymes and glucose metabolism. We saw VAT to have positive 
correlation with GPT higher than median (p < 0,05), with an OR of 1,6. 
Other matching didn’t show any significant result. All the studies we 
performed to assess odds ratio are displayed in table 9, table 10, table 11 
and table 12. 
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3.3 DISCUSSION 
 
Obesity is known to be a major public health problem. Due to its 
currently increasing high prevalence and adverse effects on health, our 
life expectancy has been projected to decline for the first time since the 
last decades. This is in part due to obesity increasing significantly risk 
for cardio-metabolic diseases, such as cardiovascular disease and type-2 
diabetes mellitus, which in turn are the major causes of morbidity and 
mortality in the industrialized world. This obesity-related risk for cardio 
vascular diseases is also a consequence of adipose tissue releasing a 
number of adipocytokines that, once released into the circulation, 
promote the development of metabolic derangements. 
For many years, obesity has been assessed with body mass index which 
is an imprecise, and possibly misleading, metric of body fat; waist 
circumference and waist to height ratio are also easy to measure. BMI 
and waist circumference are influenced not only by fat mass but also by 
muscle mass and bone mass, among others. Furthermore, obesity-
related risk for cardiovascular diseases increases not only with the 
quantity but also with a specific distribution of body fat: individuals 
who store body fat viscerally rather than elsewhere in the body (mostly 
subcutaneously) are at a greater risk for CVD. Several mechanistic 
pathways have been proposed to underlie the link between visceral fat 
and cardiovascular diseases: intra abdominal adipose tissue, as 
compared with subcutaneous adipose tissue, exhibits a more adverse 
secretory profile and higher lipid turnover. Further, visceral fat but 
drains directly to the portal circulation and liver, where it enhances 
dyslipidemia and insulin resistance, key mediators of the link between 
obesity and cardiometabolic diseases. The role of visceral fat 
involvement in metabolic derangements in adulthood has been largely 
investigated, but it’s still under study for what concerns evolutive age. 
Despite the critical role of VF in metabolic syndrome pathogenesis and 
the recent emergence of MS in adolescence, only a few large-scale 
population-based studies quantified visceral fat directly. Magnetic 
Resonance Imaging and Computed Tomography scan are known to be 
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the most precise methodic to study body fat composition, but because of 
their costs and the problem of radiations, other accurate fat mass 
evaluations need to be found. In most population-based studies, 
abdominal obesity is measured indirectly with WC.  
First aim of our study was to evaluate visceral fat with ultrasonography 
and see its correlation with other fat tissue assessment during evolutive 
age.  
Our cohort of patients showed a significant difference of VAT between 
the two sexes, even after matching subjects for BMI, like Kotani et Al. 
and Goran et Al. already postulated in 1994 and 1995: sexual 
dimorphism of visceral fat supports that there is a definite gender 
difference in the age-related changes in whole-body fat distribution, 
especially in the abdominal fat tissues; sex differences in intraabdominal 
adipose tissue begin to emerge during pubertal development, with boys 
having more VAT than girls.  
The present study revealed a significant correlation between visceral fat 
and all the other anthropometric measures; regression analysis showed 
that among the measurements used in this study, the best predictor of 
visceral fat is waist to height ratio. Although the best predictor of 
ultrasonography measured visceral fat, as per this study, is waist to 
height, as already stated before the predictive power of WC is low as 
WC does not distinguish visceral adiposity from the amount of 
subcutaneous abdominal fat, and thus, it cannot reflect fat redistribution 
and the coincidence rate of WC with VFA changes with the increase of 
age; it probably should therefore be considered a marker of total 
adiposity rather than VAT. With the data in our possess so far, we want 
to futher investigate this problem, in order to establish if assessment of 
visceral fat in children should be better done by an imaging modality 
and not indirectly from anthropometric measurements.  
Previous studies have revealed that visceral adipose tissue has high 
activities of both lipogenesis and lipolysis, and its accumulation induces 
a high content of free fatty acids in portal circulation which goes into the 
liver directly. Excess free fatty acid may cause the enhancement of lipid 
synthesis and gluconeogenesis as well as insulin resistance, resulting in 
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hyperlipidemia, glucose intolerance, hypertension, and atherosclerosis. 
Thus, excess visceral adipose tissue is believed to be an important 
contributor to the development of cardiovascular diseases. In the 
present study, VFA was observed to be closely associated with glucose 
metabolic risk factors including high fasting glucose and insulin 
resistance. This finding confirms that visceral adipose tissue is 
associated with glucose metabolism in evolutive age as well as in adult 
age, as already postulated.  
As regards hepatic function, no significant correlations were found 
between visceral fat and transaminase; nevertheless a strong correlation 
was found with γGT, demonstrating visceral fat to be an important 
predictor for hepatic functioning derangements. 
The association between visceral adipose tissue and lipid metabolism 
biomarkers is not so evident in our study. After adjustment for age, sex 
and BMI, we didn’t find any significant correlation between intra 
abdominal adipose tissue and lipid status. A high triglycerides level has 
been shown to be a risk factor for cardiovascular diseases, while HDL is 
inversely correlated with the risk of CVD and a low HDL level is one of 
the hallmarks of the metabolic syndrome, but none of this derangements 
where significantly correlated with the visceral fat accumulation in our 
cohort of patients.  
Last aim of our study was to see if the increment of visceral fat could be 
a major predictor of the risk for metabolic derangements. The results we 
had from odds ratio statistical analysis show that no significant 
relationship could be found between VAT and the presence of metabolic 
syndrome or its diagnostic criteria such as high triglycerides, high 
fasting glucose, low HDL, high blood pressure; a good correlation, even 
if not significant, was found with insulin resistance, suggesting once 
again visceral fat deposit to be involved in glucose derangements and in 
diabetes mellitus type 2 onset. The only significant correlation was 
found with VF to be a major risk to have high γGT, showing an odds 
ratio of 11,3. To better investigate the role of visceral fat accumulation 
and metabolic derangements, we tried to calculate odds ratio between 
VAT and the risk of being above median value for each blood test: once 
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again, significant correlation was found between US visceral fat and 
GPT higher than the median value, showing how VAT accumulation is 
involved in liver functioning. This finding is very important as it shows 
how the VAT can be a method that reveals on a very early stage 
metabolic risk factors, before they reach values above the threshold. 
Limitations in this study could be that we only performed cross 
sectional study, and it doesn’t allow causality interferences, but only 
associations; moreover the population we studied is not representative 
for the general population. At last, ultrasonography is not the gold 
standard although it is validated. On the other hand, our points of 
strength are that direct measurements of fat amount with gold standard 
method and direct measure of fat distribution although not gold 
standard showed important elements in favor of the use of the U.S. in 
the normal clinical practice. 
The results we have presented among children and adolescent are very 
similar to those presented for adults so far, showing probably similar 
pathways in the visceral fat accumulation and in its metabolic 
significance. Further studies will be held to better investigate the 
importance of visceral fat accumulation in evolutive age as a predictor 
for metabolic derangements. 
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4 TABLES AND GRAPHS 
 
Table 1 
 
TOTAL (n 83) MALES (n 25) FEMALES (n 58) 
 
MIN MAX MEAN 
(SD) 
MIN MAX MEAN 
(SD) 
MIN MAX MEAN 
(SD) 
AGE (years) 11 17 14,64 
(1,90) 
11 17 14,56 
(2,06) 
11 17 14,67 
(1,84) 
Z-BMI -0,87 1,81 1,38 
(0,70) 
-0,87 2,81 1,70 
(0,77) 
-0,52 2,40 1,25** 
(0,63) 
Z-WC -0,34 7,74 3,40 
(1,68) 
-0,34 7,74 3,52 
(1,99) 
-0,03 6,58 3,34 
(1,55) 
SAT (cm) 0,33 5,79 2,84 
(1,13) 
0,33 5,79 3,01 
(1,32) 
0,44 5,41 2,76 
(1,04) 
VAT (cm) 1,18 8,57 3,32 
(1,35) 
1,47 8,57 4,18 
(1,70) 
1,18 5,56 2,95** 
(0,96) 
VAT/SAT 0,40 7,06 1,39 
(0,97) 
0,62 7,06 1,77 
(1,41) 
0,40 4,36 1,23 
(0,65) 
FFM (Kg) 28,1 86,4 46,7 
(11,1) 
28,1 86,4 54,91 
(15,38) 
28,2 55,4 43,25 
(6,01) 
FAT % 9,4 54,1 35,8 
(8,2) 
9,4 48,9 33,38 
(10,54) 
16,9 54,1 36,89** 
(6,88) 
TOT FAT (g) 7366 61951 26764 
(9467) 
7366 61951 28851 
(13451) 
9771 41670 25865** 
(7073) 
TRUNK/LIMB 0,51 1,43 0,86 
(0,18) 
0,62 1,43 0,93 
(0,2) 
0,51 1,25 0,83 
(0,16) 
Abbreviation: BMI: body mass index; WC: waist circumference; VAT: visceral abdominal tissue; 
SAT: superficial abdominal tissue; FFM: fat free mass measured with BODPOD, TOT FAT: total 
fat measured with DEXA; TRUNK/LIMB: trunk fat/limbs fat ratio; **: significance p < 0,05 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
Table 2 
 TOTAL (n 83) MALES (n 25) FEMALES (n 58) 
 MIN MAX MEAN 
(SD) 
MIN MAX MEAN 
(SD) 
MIN MAX MEAN 
(SD) 
Chol. 
(mg/dL) 
111 322 170 
(43,4) 
111 322 173 
(43,4) 
112 237 168 (27,8) 
LDL 
(mg/dL) 
48 160 96   
(28,3) 
54 160 103 
(28,3) 
48 150 93    (23,0) 
HDL 
(mg/dL) 
32 97 58   
(12,4) 
32 82 50   
(12,4) 
41 97 61**   (12,7) 
Triglyc 
(mg/dL) 
23 759 75 
(143,1) 
23 759 105 
(143,1) 
29 211 62**   (29,1) 
Glycemia 
(mg/dL) 
70 106 88     
(6,1) 
81 106 93     
(6,1) 
70 106 86**     (6,6) 
Insulin 
(mIU/L) 
2,5 68,1 13    
(12,2) 
7,2 68,1 17   
(12,2) 
2,5 36,9 11**     (6,1) 
HOMA ,51 16,99 3,00 
(3,08) 
1,71 16,99 4,16 
(3,08) 
,51 7,92 2,51** (1,42) 
GOT 
(IU/L) 
11 34 19     
(5,0) 
14 34 23     
(5,0) 
11 34 18**     (5,2) 
GPT 
(IU/L) 
9 48 18     
(8,8) 
13 42 24     
(8,8) 
9 48 16**     (6,8) 
γGT 
(IU/L) 
4,0 49,4 15    
(11,1) 
10,5 49,4 21,4 
(11,1) 
4,0 48,9 12**     (6,6) 
Abbreviation: Chol: total cholesterol; LDL: low density lipoprotein; HDL high density 
lipoprotein; Triglyc: triglycerides; HOMA: Homeostasis Model for Assessment of Insulin 
Resistance; GOT: glutamic oxaloacetic transaminase; GPT: glutamic pyruvic transaminase; γGT: 
gamma glutamyl transpeptidase; **: significance p < 0,05 
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Table 3 
 TOTAL MALES FEMALES 
Overweight  27 (32,5%) 4 (16,0%)  23 (39,6%) 
Obese  32 (38,5%) 17 (68,0%)  15 (25,8%)** 
Hyperglycemia  5 (6,0%) 4 (16,0%)  1 (1,7%)** 
Hypertriglycerides  4 (4,8%) 3 (12,0%)  1 (1,7%)** 
Low HDL  7 (8,4%) 7 (28,0%)  0 (0%)** 
High blood pressure  11 (13,2%) 8 (32,0%)  3 (5,1%)** 
Metabolic syndrome  5 (6,0%) 6 (24,0%)  0 (0%)** 
Insulin resistance  40 (48,1%) 17 (68,0%)  23 (39,6%)** 
Abbreviation: HDL: high density lipoprotein; **: significance p < 0,05 
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Table 4 
  Z-BMI Z-WC SAT VAT VAT/SAT FAT % TOT FAT  T/L 
Z-BMI R 
SIG 
1 
 
0,807 
# 
0,711 
# 
0,518 
# 
-0,427 
# 
0,596 
# 
0,762 
# 
0,460 
# 
Z-WC R 
SIG 
0,807 
# 
1 
 
0,800 
# 
0,471 
# 
-0,434 
# 
0,610 
# 
0,807 
# 
0,571 
# 
SAT (cm) R 
SIG 
0,711 
# 
0,800 
# 
1 
 
0,396 
# 
-0,892 
# 
0,598 
# 
0,745 
# 
0,645 
# 
VAT (cm) R 
SIG 
0,518 
# 
0,471 
# 
0,396 
# 
1 
 
-0,212 
# 
0,329 
# 
0,514 
# 
0,322 
# 
VAT/SAT R 
SIG 
-0,427 
# 
-0,434 
# 
-0,592 
# 
0,212 
# 
1 
 
-0,431 
# 
-0,402 
# 
-0,324 
# 
FAT % R 
SIG 
0,596 
# 
0.610 
# 
0,598 
# 
0,329 
# 
-0,431 
# 
1 
 
0,698 
# 
0,248 
# 
TOT FAT (g) R 
SIG 
0,762 
# 
0,823 
# 
0,745 
# 
0,514 
# 
-0,402 
# 
0,698 
# 
1 
 
0,477 
# 
T/L FAT R 
SIG 
0,490 
# 
0,571 
# 
0,645 
# 
0,322 
# 
-0,324 
# 
0,248 
# 
0,477 
# 
1 
 
Abbreviation: Z-BMI: body mass index z-score; Z-WC: waist circumference z-score; SAT: 
superficial asipose tissue; VAT: visceral adipose tissue; VAT/SAT: visceral adipose 
tissue/superficial adipose tissue ratio; FAT%: total fat percentage measured with BOD POD; 
TOT FAT: total fat mass measured with DEXA; T/L FAT: trumk fat/limb fat ratio; R: Pearson’s 
correlation; SIG: significance (#: p < 0,05) 
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Table 5 
 VAT VAT (sport) 
 Coeff. Stand.Er. T p Coeff. Stand.Er. T p 
Z-WEIGHT 
 
0,323 0,156 3,287 0,002** 0,313 0,155 3,211 0,002** 
Z-BMI 
 
0,425 0,188 4,320 0,000** 0,410 0,188 4,166 0,000** 
Z-WC 
 
0,444 0,071 5,023 0,000** 0,430 0,071 4,810 0,000** 
WAIST/HEIGHT 
 
0,542 1,986 6,132 0,000** 0,528 2,007 5,910 0,000** 
BODY FAT % 
 
0,419 0,015 4,515 0,000** 0,404 0,015 4,351 0,000** 
FAT FREE MASS  
 
0,101 0,017 0,740 0,461 0,127 0,016 0,935 0,353 
TOTAL FAT 
 
0,510 0,038 5,847 0,000** 0496 0,045 5,630 0,000** 
TRUNK/LIMB  
 
0,252 0,742 2,477 0,015** 0,241 0,739 2,375 0,020** 
Abbreviation: Coeff; coefficient; Stand. Er.: standard error; VAT: visceral adipose tissue; VAT 
(sport): visceral adipose tissue regression corrected for physical activity; Z-WEIGHT: weight z-
score; Z-BMI: BMI z-score; WAIST/HEIGHT: waist to height ratio; BODY FAT %: total fat 
percentage measured with BOD POD; FAT FREE MASS: total lean mass measured with BOD 
POD; TOTAL FAT: total fat mass measured with DEXA; TRUNK/LIMB: trunk fat/limbs fat ratio 
SIG: **: significance p < 0,05 
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Table 6 
 SAT SAT (sport) 
  Coeff. Stand.Er. T p Coeff. Stand.Er. T p 
Z-WEIGHT 
 
 
 
0,700 0,113 3,287 0,000** 0,691 0,112 8,199 0,000** 
Z-BMI 
 
 
 
0,805 0,129 10,035 0.000** 0,793 0,129 9,872 0,000** 
Z-WC 
 
 
 
0,805 0,045 12,108 0,000** 0,796 0,045 11,828 0,000** 
WAIST/HEIGHT 
 
 
 
0,829 1,386 11,295 0,000** 0,819 1,403 11,020 0,000** 
BODY FAT % 
 
 
 
0,658 0,012 7,468 0,000** 0,645 0,013 7,245 0,000** 
FAT FREE 
MASS  
 
 
 
0,401 0,015 2,778 0,007** 0,433 0,015 3,040 0,003** 
TOTAL FAT 
 
 
 
0,773 0,468 10,153 0,000** 0,762 0,438 9,896 0,000** 
TRUNK/LIMB  
 
 
 
0,672 0,546 7,528 0,000** 0,661 0,543 7,454 0,000** 
Abbreviation: Coeff; coefficient; Stand. Er.: standard error; SAT: superficial asipose tissue; SAT 
(sport): superficial adipose tissue regression corrected for physical activity; Z-WEIGHT: weight 
z-score; Z-BMI: BMI z-score; WAIST/HEIGHT: waist to height ratio; BODY FAT %: total fat 
percentage measured with BOD POD; FAT FREE MASS: total lean mass measured with BOD 
POD; TOTAL FAT: total fat mass measured with DEXA; TRUNK/LIMB: trunk fat/limbs fat ratio 
SIG: **: significance p < 0,05 
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Table 7 
 VAT/SAT VAT/SAT (sport) 
  Coeff. Stand.Er. T p Coeff. Stand.Er. T p 
Z-WEIGHT 
 
 -0,559 0,106 -6,013 0,000** -0,563 0,106 -6,036 0,000** 
Z-BMI 
 
 -0,611 0,130 -6,437 0,000** -0,623 0,131 -6,535 0,000** 
Z-WC 
 
 -0,458 0,055 -4,775 0,000** -0,473 0,056 -4,890 0,000** 
WAIST/HEIGHT 
 
 -0,427 1,689 -4,090 0,000** -0,443 1,709 -4,190 0,000** 
BODY FAT % 
 
 -0,412 0,012 -4,072 0,000** -0,422 0,012 -4,136 0,000** 
FAT FREE MASS  
 
 -0,411 0,012 -2,962 0,004** -0,411 0,012 -2,923 0,005** 
TOTAL FAT 
 
 -0,453 0,578 -4,547 0,000** -0,468 0,569 -4,656 0,000** 
TRUNK/LIMB  
 
 -0,416 0,541 -4,037 0,000** -0,421 0,544 -4,063 0,000** 
Abbreviation: Coeff; coefficient; Stand. Er.: standard error; VAT/SAT: visceral adipose 
tissue/superficial adipose tissue ratio; VAT/SAT (sport): visceral adipose tissue/superficial 
adipose tissue ratio regression corrected for physical activity; Z-WEIGHT: weight z-score; Z-
BMI: BMI z-score; WAIST/HEIGHT: waist to height ratio; BODY FAT %: total fat percentage 
measured with BOD POD; FAT FREE MASS: total lean mass measured with BOD POD; TOTAL 
FAT: total fat mass measured with DEXA; TRUNK/LIMB: trunk fat/limbs fat ratio SIG: **: 
significance p < 0,05 
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Table 8 
 VAT SAT VAT/SAT 
 
C
o
e
ff
. 
S
ta
n
d
.E
r.
 
T
 
p
 
C
o
e
ff
. 
S
ta
n
d
.E
r.
 
T
 
p
 
C
o
e
ff
. 
S
ta
n
d
.E
r.
 
T
 
p
 
Chol. 
(mg/dL) 
0,039 0,004 0,421 0,675 0,014 0,003 0,182 0,856 0,042 0,003 0,467 0,6422 
LDL 
(mg/dL) 
0,112 0,005 1,161 0,249 0,082 0,004 1,048 0,298 0,047 0,004 0,500 0,618 
HDL 
(mg/dL) 
-0,079 0,010 -,768 0,445 -0,095 0,007 -,940 0,258 0,004 0,007 0,042 0,697 
Triglyc 
(mg/dL) 
-0,006 0,002 -,060 0,953 -0,042 0,001 -,534 0,595 0,014 0,001 0,149 0,882 
Glycemia 
(mg/dL) 
0,206 0,018 2,126 0,037* 0,220 0,013 2,794 0,086 0,013 0,013 0,132 0,896 
Insulin 
(mIU/L) 
0,288 0,016 2,680 0,009* 0,019 0,012 0,211 0,832 0,235 0,012 2,243 0,028* 
HOMA 
 
0,272 0,066 2,555 0,013* 0,017 0,047 0,192 0,848 0,214 0,046 2,055 0,043* 
GOT 
(IU/L) 
0,024 0,025 0,235 0,815 0,178 0,016 2,182 0,032* -0,001 0,017 -,012 0,991 
GPT 
(IU/L) 
0,124 0,017 1,159 0,250 0,015 0,012 0,177 0,860 0,195 0,012 1,927 0,058 
γGT 
(IU/L) 
0,324 0,015 3,262 0,002* 0,049 0,010 0,572 0,569 0,149 0,011 1,477 0,144 
Abbreviation: Coeff; coefficient; Stand. Er.: standard error; Chol: total cholesterol; LDL: low 
density lipoprotein; HDL high density lipoprotein; Triglyc: triglycerides; HOMA: Homeostasis 
Model for Assessment of Insulin Resistance; GOT: glutamic oxaloacetic transaminase; GPT: 
glutamic pyruvic transaminase; γGT: gamma glutamyl transpeptidase; VAT: visceral adipose 
tissue; SAT: superficial asipose tissue; VAT/SAT: visceral adipose tissue/superficial adipose 
tissue ratio; SIG: *: significance p < 0,05 
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Table 9 
 VAT 
SIGNIFICANCE (p) ODDS RATIO 
METABOLIC SYNDROME 0,681 1,156 
HYPERGLYCEMIA 0,503 1,267 
INSULIN RESISTANCE 0,059 1,704 
HYPERCHOLESTEROLEMIA 0,754 1,089 
HYPERTRIGLYCERIDEMIA 0,058 2,164 
HYPO HDL 0,919 1,034 
HIGH GOT - - 
HIGH GPT 0,197 1,802 
HIGH γGT 0,009** 11,332 
HIGH BP 0,832 0,945 
Abbreviation: HDL high density lipoprotein; GOT: glutamic oxaloacetic transaminase (no values 
above limit); GPT: glutamic pyruvic transaminase; γGT: gamma glutamyl transpeptidase; BP: 
arterial blood pressure; VAT: visceral adipose tissue; **: significance p < 0,05 
 
 
 
Table 10 
 Z-WC 
SIGNIFICANCE (p) ODDS RATIO 
METABOLIC SYNDROME 0,514 0,719 
HYPERGLYCEMIA 0,988 0,993 
INSULIN RESISTANCE 0,705 1,102 
HYPERCHOLESTEROLEMIA 0,628 0,848 
HYPERTRIGLYCERIDEMIA 0,482 0,699 
HYPO HDL 0,308 0,625 
HIGH GOT - - 
HIGH GPT 0,666 0,773 
HIGH γGT 0,302 1,682 
HIGH BP 0,420 0,757 
Abbreviation: Z-WC: waist circumference z-score; HDL high density lipoprotein; GOT: glutamic 
oxaloacetic transaminase (no values above limit); GPT: glutamic pyruvic transaminase; γGT: 
gamma glutamyl transpeptidase; BP: arterial blood pressure; VAT: visceral adipose tissue; **: 
significance p < 0,05 
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Table 11 
 TOTAL FAT 
SIGNIFICANCE (p) ODDS RATIO 
METABOLIC SYNDROME 0,209 0,987 
HYPERGLYCEMIA 0,331 0,630 
INSULIN RESISTANCE 0,481 1,231 
HYPERCHOLESTEROLEMIA 0,764 0,493 
HYPERTRIGLYCERIDEMIA 0,941 0,899 
HYPO HDL 0,226 0,475 
HIGH GOT - - 
HIGH GPT 0,348 0,787 
HIGH γGT 0,014** 4,743 
HIGH BP 0,757 0,797 
Abbreviation: TOTAL FAT: total fat mass measured with DEXA; HDL high density lipoprotein; 
GOT: glutamic oxaloacetic transaminase (no values above limit); GPT: glutamic pyruvic 
transaminase; γGT: gamma glutamyl transpeptidase; BP: arterial blood pressure; VAT: visceral 
adipose tissue; **: significance p < 0,05 
 
 
 
Table 12 
 VISCERAL FAT 
SIGNIFICANCE (p) ODDS RATIO 
HIGH GLYCEMIA 0,086 1,452 
INSULIN RESISTANCE 0,079 1,647 
HIGH CHOLESTEROL 0,255 1,257 
HIGH LDL 0,248 1,282 
HIGH TRIGLYCERIDES 0,697 1,079 
HYPO HDL 0,084 1,453 
HIGH GOT 1,839 1,040 
HIGH GPT 0,038** 1,649 
HIGH γGT 0,313 1,239 
All the values tested are intended to be over (high) or under (low) the median value. 
Abbreviation: LDL: low density lipoproteine; HDL high density lipoprotein; GOT: glutamic 
oxaloacetic transaminase (no values above limit); GPT: glutamic pyruvic transaminase; γGT: 
gamma glutamyl transpeptidase; VAT: visceral adipose tissue; **: significance p < 0,05 
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Graph 1 
 
 
Abbreviations: VAT: visceral abdominal tissue; Z-BMI: body mass index z-score 
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Graph 2 
 
Abbreviations: VAT: visceral abdominal tissue; Z-WC: waist circumference z-score 
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Graph 3 
 
Abbreviations: VAT: visceral abdominal tissue; WAIST/HEIGHT: waist to height ratio 
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Graph 4 
 
Abbreviations: VAT: visceral abdominal tissue; FM%: fat mass percentage measured with BOD 
POD 
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Graph 5 
 
Abbreviations: VAT: visceral abdominal tissue; TOTAL FAT: total fat mass measured with 
DEXA 
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Graph 6 
 
Abbreviations: VAT: visceral abdominal tissue; TRUNK/LIMBS: trunk fat/limbs fat measured 
with DEXA 
 
 
 
 
 
 
 
 
